Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryFeb072013	Fate Therapeutics to Present at 15th Annual BIO CEO & Investor Conference SAN DIEGO, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, today announced that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will be presenting a company overview Read All »	View HTML Fate Therapeutics to Present at 15th Annual BIO CEO & Investor Conference 9.8 KB
Toggle SummaryDec042012	Fate Therapeutics Strengthens Leadership Position in the Development of Wnt-Based Protein Therapeutics Fate Therapeutics Strengthens Leadership Position in the Development of Wnt-Based Protein Therapeutics San Diego, CA – Fate Therapeutics, Inc. , a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today several advancements in its goal Read All »	View HTML Fate Therapeutics Strengthens Leadership Position in the Development of Wnt-Based Protein Therapeutics 11.2 KB
Toggle SummaryNov272012	Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies San Diego, CA – Fate Therapeutics, Inc. , a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today the initiation of a Read All »	View HTML Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies 12 KB
Toggle SummaryOct152012	Fate Therapeutics Appoints Christian Weyer as President and Chief Executive Officer Fate Therapeutics Appoints Christian Weyer as President and Chief Executive Officer San Diego, CA – Fate Therapeutics, Inc. announced today that Christian Weyer, M.D., M.A.S. has been appointed President and Chief Executive Officer and elected to the Company’s Board of Directors, Read All »	View HTML Fate Therapeutics Appoints Christian Weyer as President and Chief Executive Officer 11.3 KB
Toggle SummaryJun112012	Fate Therapeutics and BD Biosciences Launch BD SMC4 to Improve Cellular Reprogramming and IPS Cell Culture Applications San Diego, CA – Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced pluripotent stem cell (iPSC)-related product resulting from the collaboration between the two companies. Read All »	View HTML Fate Therapeutics and BD Biosciences Launch BD SMC4 to Improve Cellular Reprogramming and IPS Cell Culture Applications 11.3 KB
Toggle SummaryDec142011	Fate Therapeutics Announces the Appointment of William H. Rastetter as Chairman and Interim CEO San Diego, CA – Fate Therapeutics, Inc. announced today that it has appointed William H. Rastetter Ph.D. as Chairman and Interim Chief Executive Officer. Dr. Rastetter served as Chief Executive Officer of IDEC Pharmaceuticals from December 1986 through November 2003, and as Chairman from May Read All »	View HTML Fate Therapeutics announces the appointment of William H. Rastetter as Chairman and Interim CEO 188.1 KB
Toggle SummaryDec132011	Fate Therapeutics Announces Promising Data From Phase 1B Study of ProHema at the 2011 American Society of Hematology Annual Conference Data Support the Potential Benefit of a Novel Ex Vivo Cell Modulation Approach to Improving Engraftment in Patients Undergoing Umbilical Cord Blood Transplantation Read All »	View HTML Fate Therapeutics announces promising data from Phase 1B study of ProHema at the 2011 American Society of Hematology Annual Conference 15.3 KB
Toggle SummaryDec082011	Fate Therapeutics Secures Foundational Patent for IPS Cell Programming U.S. Patent Covers Key Compositions Used in the Generation of Human Induced Pluripotent Stem Cells Read All »	View HTML Fate Therapeutics secures foundational patent for IPS cell programming 136.2 KB
Toggle SummaryNov162011	Fate Therapeutics Strengthens its iPSC Platform Secures U.S. Patent to Novel Small Molecule Modulator of Pluripotent Stem Cells Read All »	View HTML Fate Therapeutics strengthens its iPSC platform 10 KB
Toggle SummaryMay092011	Takeda Ventures Makes Strategic Investment in Fate Therapeutics Joins Strategic Investor Syndicate of Fate that Includes Four Pharmaceutical Companies Read All »	View HTML Takeda Ventures makes strategic investment in Fate Therapeutics 15.1 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.